{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:45:42Z","timestamp":1789933542800,"version":"4.0.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The development of the oral tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML) is one of the great triumphs of cancer research. Although the efficacy of TKIs has dramatically improved the disease-specific overall survival rate, the prevalence of CML is increasing worldwide. Currently, CML patients receive prolonged (even lifelong) treatment, and over the last decade, clinical decision making has become challenging. Therefore, consideration of the effects of TKI therapies on patients\u2019 quality of life (QoL) and symptom burden (ie, patient-reported outcomes [PROs]) is now critical to more robustly inform patient care and improve health care quality. Over the last 5 years, a number of studies have generated valuable PRO data, for example, on long-term QoL effects of imatinib therapy or symptom burden of patients switching from imatinib to second-generation TKIs. PRO findings are important, as they provide a unique patient perspective on the burden of the disease and treatments effects. We will review main evidence-based data on the use of PROs in clinical research and highlight the importance of methodological rigor of PRO assessment. Also, we will describe the potential value of using PRO assessment in routine clinical practice, for example, to facilitate timely management of side effects. Areas for future research will also be discussed.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.170","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"170-179","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors"],"prefix":"10.1182","volume":"2016","author":[{"given":"Fabio","family":"Efficace","sequence":"first","affiliation":[{"name":"Data Center and Health Outcomes Research Unit, Gruppo Italiano Malattie EMatologiche dell\u2019Adulto (GIMEMA), Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cannella","sequence":"additional","affiliation":[{"name":"Data Center and Health Outcomes Research Unit, Gruppo Italiano Malattie EMatologiche dell\u2019Adulto (GIMEMA), Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"22","key":"2019111703340154600_B1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for Progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"2019111703340154600_B2","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94","author":"H\u00f6glund","year":"2015","journal-title":"Ann Hematol"},{"issue":"7","key":"2019111703340154600_B3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"2019111703340154600_B4","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.152.152","article-title":"Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056) [abstract]","volume":"124","author":"Cortes","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2019111703340154600_B5","article-title":"Impact of treatment with frontline nilotinib (NIL) vs imatinib (IM) on sustained deep molecular response (MR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) [abstract]","volume":"126","author":"Hochhaus","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111703340154600_B6","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1182\/blood-2015-06-641043","article-title":"Is there a best TKI for chronic phase CML?","volume":"126","author":"Larson","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019111703340154600_B7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrclinonc.2015.29","article-title":"Patient-reported outcomes as end points and outcome indicators in solid tumours","volume":"12","author":"Secord","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"2019111703340154600_B8","unstructured":"US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: Use in medical product development to support labeling claims. US Department of Health and Human Services Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf. Accessed 29 April 2016."},{"issue":"5","key":"2019111703340154600_B9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2019111703340154600_B10","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111703340154600_B11","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111703340154600_B12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2015.222","article-title":"Patient-reported outcomes in the evaluation of toxicity of anticancer treatments","volume":"13","author":"Di Maio","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2019111703340154600_B13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3324\/haematol.2013.094045","article-title":"Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden","volume":"99","author":"Baccarani","year":"2014","journal-title":"Haematologica"},{"issue":"19","key":"2019111703340154600_B14","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","article-title":"A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"120","author":"Radich","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111703340154600_B15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111703340154600_B16","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111703340154600_B17","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"28","key":"2019111703340154600_B18","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111703340154600_B19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2015.0530","article-title":"Patient-reported outcomes in cancer drug development and US regulatory review: perspectives from industry, the Food and Drug Administration, and the patient","volume":"1","author":"Basch","year":"2015","journal-title":"JAMA Oncol"},{"issue":"12","key":"2019111703340154600_B20","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1158\/1078-0432.CCR-12-0653","article-title":"U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis","volume":"18","author":"Deisseroth","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2019111703340154600_B21","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study","volume":"21","author":"Hahn","year":"2003","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111703340154600_B22","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2019111703340154600_B23","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","article-title":"Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib","volume":"27","author":"Efficace","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2019111703340154600_B24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.leukres.2012.09.013","article-title":"Health-related quality of life in chronic myeloid leukemia","volume":"37","author":"Trask","year":"2013","journal-title":"Leuk Res"},{"issue":"4","key":"2019111703340154600_B25","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.leukres.2011.10.011","article-title":"Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia","volume":"36","author":"Trask","year":"2012","journal-title":"Leuk Res"},{"issue":"8","key":"2019111703340154600_B26","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1185\/03007995.2016.1174108","article-title":"Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure","volume":"32","author":"Whiteley","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"2019111703340154600_B27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clml.2016.02.002","article-title":"Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study","volume":"16","author":"Cortes","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2019111703340154600_B28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/10428194.2015.1049166","article-title":"Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients","volume":"57","author":"Park","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2019111703340154600_B29","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"2019111703340154600_B30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","article-title":"International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24","volume":"23","author":"Efficace","year":"2014","journal-title":"Qual Life Res"},{"issue":"5","key":"2019111703340154600_B31","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood-2013-01-477687","article-title":"Measuring the symptom burden associated with the treatment of chronic myeloid leukemia","volume":"122","author":"Williams","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111703340154600_B32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ajh.24275","article-title":"Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring","volume":"91","author":"Jabbour","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111703340154600_B33","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.25648","article-title":"Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications","volume":"117","author":"Pinilla-Ibarz","year":"2011","journal-title":"Cancer"},{"issue":"11","key":"2019111703340154600_B34","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1185\/03007995.2014.944973","article-title":"Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase","volume":"30","author":"Gu\u00e9rin","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"2019111703340154600_B35","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3324\/haematol.2013.093724","article-title":"Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia","volume":"99","author":"Efficace","year":"2014","journal-title":"Haematologica"},{"issue":"22","key":"2019111703340154600_B36","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"issue":"14","key":"2019111703340154600_B37","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111703340154600_B38","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","article-title":"Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed","volume":"35","author":"Eliasson","year":"2011","journal-title":"Leuk Res"},{"issue":"3","key":"2019111703340154600_B39","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.leukres.2013.07.003","article-title":"Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors","volume":"38","author":"Efficace","year":"2014","journal-title":"Leuk Res"},{"issue":"3","key":"2019111703340154600_B40","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2012.082511","article-title":"Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges","volume":"99","author":"Noens","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"2019111703340154600_B41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clml.2016.02.040","article-title":"Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib","volume":"16","author":"Unnikrishnan","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2019111703340154600_B42","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2147\/PPA.S70712","article-title":"Chronic myeloid leukemia patients\u2019 adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians","volume":"8","author":"Kek\u00e4le","year":"2014","journal-title":"Patient Prefer Adherence"},{"issue":"14","key":"2019111703340154600_B43","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2013.53.5948","article-title":"What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials","volume":"32","author":"Kotronoulas","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111703340154600_B44","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/JCO.2004.06.078","article-title":"Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial","volume":"22","author":"Velikova","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111703340154600_B45","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111703340154600_B46","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3322\/caac.21150","article-title":"Electronic patient-reported outcome systems in oncology clinical practice","volume":"62","author":"Bennett","year":"2012","journal-title":"CA Cancer J Clin"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/170\/1251007\/hem088342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/170\/1251007\/hem088342.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T08:34:27Z","timestamp":1573979667000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/170\/21096\/The-value-of-quality-of-life-assessment-in-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.170","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}